The compound proved to be least toxic and extremely effective in controlling the growth of SF295 human glioblastoma xenografts, the company said.
According to PhytoMedical, in all cases where specimens were treated for human glioblastoma brain cancer using the company’s patented compound, researchers reported a significant reduction in tumor size, prolonged lifespan of 46%-plus for the treated group versus the control group, notably enhanced chemotherapeutic effect of the compound and even observed tumor cured in one of the specimens with the deadly glioblastoma cancer.
Interpreting the data collected from these important efficacy and toxicity tests, researchers favorably surmised that PhytoMedical’s anti-cancer compound may have its selectivity in killing SF295 human glioblastoma cells, the company added.
Greg Wujek, president and CEO of PhytoMedical Technologies, said: I am elated by the results of our latest phase of efficacy and toxicity tests. The fact that one of the test specimens exhibited tumor cured with no negative side-effects is especially encouraging.
We’re now reviewing our formulation options and very much look forward to continuing our anti-cancer drug development with the hope of producing an effective treatment option against glioblastoma, a deadly disease.